|
|
Epigenetic regulation of MicrorNA-127 in the Inhibition of Uveal Melanoma cell Proliferation |
Qiongjie Cao,Jing Dong,Li Li,Xiaoyan Chen,Jiao Wang,Dongsheng Yan |
State Key Laboratory of Ophthalmology, Optometry and Vision Science, Eye Hospital of Wenzhou Medical University, Wenzhou 325027, China |
|
|
Abstract Objective: We investigated the expression and regulation of microRNA-127 (miR-127) in uveal melanoma cells. We also investigated the effect of epigenetically upregulating miR-127 by altering DNA methylation and histone acetylation. Methods: In this experimental study, we performed real-time reverse transcriptase
quantitative polymerase chain reaction (RT-qPCR) to detect the expression level of miR-127 in both uveal melanoma cells (M23 and SP6.5) and uveal melanocytes (UM95). Lipofectamine RNAiMAX reagent was used to transfect M23 and SP6.5 with either miR-127 or a negative control (NC). The proliferation of uveal melanoma cells was quantified by 3-[4, 5-dimethyl-thiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazo-lium, inner salt (MTS) cell proliferation assay. Cell cycle was examined by flow cytometry. The expression of cell cycle-related proteins was analyzed by Western Blot. In addition,RT-qPCR was performed to detect the expression level of miR-127 in M23 and SP6.5 cells after treatment with 5-aza-2-deoxycytidine (5-Aza-dC) and trichostatin A (TSA). These agents modify gene expression through DNA methylation and histone acetylation, respectively. Data were analyzed using independent t-tests. results: miR-127 was dramatically downregulated in M23 and SP6.5 cells as compared to UM95 (t=72.2, 591.5, P<0.001). The MTS assay showed that the relative number of cells transfected with miR-127 [(62.3±4.2)% and (65.4±2.3)%] was significantly lower than transfected with NC (t=12.7,21.6, P<0.001). Flow cytometry showed that the percentage of M23 and SP6.5 cells transfected with miR-127 in G0/G1 phase was significantly higher than for the NC group (t=-6.7, P=0.003; t=-9.9,P<0.001), and the percentage of M23 and SP6.5 cells in the S phase was significantly lower than for the NC group (t=8.6, P=0.001; t=12.7, P<0.001). Furthermore, miR-127 downregulated the level of phosphorylated retinoblastoma protein in uveal melanoma cells. In addition, miR-127 was upregulated after treatment with 5-Aza-dC and/or TSA (P<0.05). conclusions: Our results demonstrated that miR-127 can suppress uveal melanoma cell proliferation by inhibition of cell cycle. Furthermore miR-127 expression was modulated by epigenetic regulation including DNA methylation and histone acetylation.
|
Received: 25 May 2018
|
Fund: National Natural Foundation of China (81272286); National Natural Foundation of China for Youth (81301776) |
Corresponding Authors:
Dongsheng Yan, State Key Laboratory of Ophthalmology, Optometry and Vision Science,Eye Hospital of Wenzhou Medical University, Wenzhou 325027, China (Email: dnaprotein@hotmail.com)
|
|
|
|
[1] |
Xiao C, Rajewsky K. MicroRNA control in the immune system:basic principles. Cell, 2009, 136(1): 26-36. DOI: 10.1016/j.cell.2008.12.027.
|
[2] |
Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer, 2006, 6(11): 857-866. DOI: 10.1038/nrc1997.
|
[3] |
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 2004, 5(7): 522-531. DOI:10.1038/nrg1379.
|
[4] |
Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol, 2007, 302(1): 1-12. DOI: 10.1016/j.ydbio.2006.08.028.
|
[5] |
Singh AD, Bergman L, Seregard S. Uveal melanoma:epidemiologic aspects. Ophthalmol Clin North Am, 2005, 18(1):75-84, viii. DOI: 10.1016/j.ohc.2004.07.002.
|
[6] |
Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol, 2004,22(12): 2438-2444. DOI: 10.1200/JCO.2004.08.194.
|
[7] |
Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci, 2009,
|
50 |
(4): 1559-1565. DOI: 10.1167/iovs.08-2681.
|
[8] |
Chen X, Wang J, Shen H, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci, 2011, 52(3): 1193-1199.DOI: 10.1167/iovs.10-5272.
|
[9] |
Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci, 2013, 54(3): 2248-2256. DOI: 10.1167/iovs.12-10977.
|
[7] |
Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci, 2009,
|
50 |
(4): 1559-1565. DOI: 10.1167/iovs.08-2681.
|
[8] |
Chen X, Wang J, Shen H, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci, 2011, 52(3): 1193-1199.DOI: 10.1167/iovs.10-5272.
|
[9] |
Chen X, He D, Dong XD, et al. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. Invest Ophthalmol Vis Sci, 2013, 54(3): 2248-2256. DOI: 10.1167/iovs.12-10977.
|
[10] |
王教, 陈林华, 周仲楼, 等. MicroRNA-34a抑制葡萄膜黑色素瘤细胞增殖的研究. 中国细胞生物学学报, 2011, 33(5): 498-502.
|
[11] |
Kehrmann J, Tatura R, Zeschnigk M, et al. Impact of 5-aza-2'-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology, 2014, 142(3): 384-395.DOI: 10.1111/imm.12261.
|
[12] |
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology, 2011,118(9): 1881-1885. DOI: 10.1016/j.ophtha.2011.01.040.
|
[13] |
Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond), 2012, 26(9):1157-1172. DOI: 10.1038/eye.2012.126.
|
[10] |
王教, 陈林华, 周仲楼, 等. MicroRNA-34a抑制葡萄膜黑色素瘤细胞增殖的研究. 中国细胞生物学学报, 2011, 33(5): 498-502.
|
[14] |
Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin, 2006, 46(1): 151-166.
|
[11] |
Kehrmann J, Tatura R, Zeschnigk M, et al. Impact of 5-aza-2'-deoxycytidine and epigallocatechin-3-gallate for induction of human regulatory T cells. Immunology, 2014, 142(3): 384-395.DOI: 10.1111/imm.12261.
|
[12] |
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology, 2011,118(9): 1881-1885. DOI: 10.1016/j.ophtha.2011.01.040.
|
[13] |
Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye (Lond), 2012, 26(9):1157-1172. DOI: 10.1038/eye.2012.126.
|
[14] |
Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin, 2006, 46(1): 151-166.
|
[15] |
Yan D, Dong XD, Chen X, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One, 2012, 7(7):
|
|
e40967. DOI: 10.1371/journal.pone.0040967.
|
[16] |
Wang D, Tang L, Wu H, et al. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.IUBMB Life, 2018, 70(5): 411-419. DOI:10.1002/iub.1710.
|
[17] |
Shi L, Wang Y, Lu Z, et al. miR-127 promotes EMT and stem- like traits in lung cancer through a feed-forward regulatory loop. Oncogene, 2017, 36(12): 1631-1643. DOI: 10.1038/
|
[15] |
Yan D, Dong XD, Chen X, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One, 2012, 7(7):
|
|
e40967. DOI: 10.1371/journal.pone.0040967.
|
[16] |
Wang D, Tang L, Wu H, et al. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.IUBMB Life, 2018, 70(5): 411-419. DOI:10.1002/iub.1710.
|
[17] |
Shi L, Wang Y, Lu Z, et al. miR-127 promotes EMT and stem- like traits in lung cancer through a feed-forward regulatory loop. Oncogene, 2017, 36(12): 1631-1643. DOI: 10.1038/
|
|
onc.2016.332.
|
[18] |
Huan L, Bao C, Chen D, et al. MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-κB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci, 2016,107(3): 258-266. DOI: 10.1111/cas.12869.
|
[19] |
Zhou J, Lu S, Yang S, et al. MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem, 2014, 33(5): 1537-1546.DOI: 10.1159/000358717.
|
[20] |
Zhao Y, Yang Z, Wu J, et al. High-mobility-group protein 2 regulated by microRNA-127 and small heterodimer partner modulates pluripotency of mouse embryonic stem cells and liver tumor initiating cells. Hepatol Commun, 2017, 1(8): 816-830.DOI: 10.1002/hep4.1086.
|
|
onc.2016.332.
|
[18] |
Huan L, Bao C, Chen D, et al. MicroRNA-127-5p targets the biliverdin reductase B/nuclear factor-κB pathway to suppress cell growth in hepatocellular carcinoma cells. Cancer Sci, 2016,107(3): 258-266. DOI: 10.1111/cas.12869.
|
[19] |
Zhou J, Lu S, Yang S, et al. MicroRNA-127 post-transcriptionally downregulates Sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cell Physiol Biochem, 2014, 33(5): 1537-1546.DOI: 10.1159/000358717.
|
[21] |
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic
|
[20] |
Zhao Y, Yang Z, Wu J, et al. High-mobility-group protein 2 regulated by microRNA-127 and small heterodimer partner modulates pluripotency of mouse embryonic stem cells and liver tumor initiating cells. Hepatol Commun, 2017, 1(8): 816-830.DOI: 10.1002/hep4.1086.
|
|
myelomonocytic leukemia. Blood, 2007, 109(1): 52-57. DOI:10.1182/blood-2006-05-021162.
|
[22] |
Usami M, Kishimoto K, Ohata A, et al. Butyrate and trichostatin A attenuate nuclear factor kappa B activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res, 2008,28(5): 321-328. DOI: 10.1016/j.nutres.2008.02.012.
|
[21] |
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic
|
|
myelomonocytic leukemia. Blood, 2007, 109(1): 52-57. DOI:10.1182/blood-2006-05-021162.
|
[22] |
Usami M, Kishimoto K, Ohata A, et al. Butyrate and trichostatin A attenuate nuclear factor kappa B activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res, 2008,28(5): 321-328. DOI: 10.1016/j.nutres.2008.02.012.
|
[23] |
Cardinale JP, Sriramula S, Pariaut R, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive
|
|
rats. Hypertension, 2010, 56(3): 437-444. DOI: 10.1161/HYPERTENSIONAHA.110.154567.
|
[24] |
Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specif ic DNA demethylation in human cancer cell lines. Biochem Pharmacol,2007, 73(9): 1297-1307. DOI: 10.1016/j.bcp.2006.12.032.
|
[23] |
Cardinale JP, Sriramula S, Pariaut R, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive
|
|
rats. Hypertension, 2010, 56(3): 437-444. DOI: 10.1161/HYPERTENSIONAHA.110.154567.
|
[24] |
Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specif ic DNA demethylation in human cancer cell lines. Biochem Pharmacol,2007, 73(9): 1297-1307. DOI: 10.1016/j.bcp.2006.12.032.
|
|
|
|